While type 1 MIs continue to dominate, the prevalence of type 2 MIs has grown in recent years among Medicare beneficiaries, an observational study shows. The shift has implications for care, ...
Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...